(Boursier.com) — Under the chairmanship of Thierry Chapusot, the Board of Directors ofEquasens met on March 24, 2023, in the presence of the Statutory Auditors, to examine and approve the financial statements for the 2022 financial year. The audit procedures on the consolidated financial statements have been carried out. The certification report will be issued after verification of the management report and finalization of the procedures required for the publication of the annual financial report.
The Group recorded revenue of 214.07 ME, up 10.88% compared to December 31, 2021. On a like-for-like basis (including PROKOV Editions in Q4), 2022 revenue is up by 8, 82% at 210.09 ME. The Group confirms the efficiency of its interoperability strategy between healthcare professionals and establishments with the identified challenge of structuring the healthcare offer, improving the coordination of healthcare players and the exchange of data around the patient.
The Current Operating Result of 56.79 ME is up by 12.57% compared to 2021. The Net Result increases by 18.35% to 48.70 ME, including IP BOX net of 7.74 ME. Basic earnings per share of 3.09 euros increased by 18.52% (2.60 euros in 2021).
At balance sheet level, the Group retains its strong investment capacity with gross cash at €119.20 million as of December 31, 2022. In addition, as of December 31, 2022, the company holds 142,428 shares for €10.02 million.
The shareholders’ equity of the consolidated entity amounted to 196.80 ME at December 31, 2022 compared to 165.24 ME at the end of 2021. The Group confirms its growth potential thanks to a high level of cash, a self-financing capacity in growth of +17.07% to 62.05 ME and a reduction in its financial debts.
For more than 10 years, the Equasens Group has created value for its shareholders and maintained its effort to distribute dividends. The Group will propose to the Annual General Meeting of June 29, 2023 the payment of a gross dividend of €1.15 per share (+9.52%).
2023 OUTLOOK
In 2022, the Equasens Group confirmed the efficiency of its growth strategy (organic and external) and the Ségur referencing of its software confirmed its know-how and technological expertise.
The Group also confirms its financial solidity (no net debt and a positive net cash position of 56.26 ME), which enables it to maintain its ambitions for expansion in Europe and development in other areas of health.
Upcoming meetings
-End of April 2023: Availability of the 2022 Universal Registration Document
– May 11, 2023: 2023 1st quarter turnover press release
-June 29, 2023: Annual General Meeting
-August 3, 2023: 2023 first-half turnover press release.